P/B
10,1
Savara
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
$1.1B
Market Cap • 11/10/2026
1995
(31 years)
Founded
1996
(30 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
0,5
EPS
—
Market Cap
Market Cap
1,1B
EV
986,1M
EV/Revenue
0
EV/EBITDA
-6,3
EV/EBIT
-6,3
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-12,5%
Total Yield
-12,5%
Payout
0%
Retained Earnings
-728,6M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
650,5%
Capex/OCF
-0,5%
SBC/OCF
—
% PPE
0,5%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
29%
CAGR Net Income 5Y
27,4%
CAGR EPS 5Y
4,1%
CAGR OCF 5Y
24,8%
Leverage
N.D./EBITDA
0,6
Debt/Equity
0%
Current Ratio
8,5
Quick Ratio
7,8
Interest Coverage
4375,8%
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!